Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Mar. 31, 2021 | Jul. 02, 2021 | Sep. 30, 2020 | |
Document Information [Line Items] | |||
Entity Registrant Name | GB SCIENCES INC | ||
Entity Central Index Key | 0001165320 | ||
Current Fiscal Year End Date | --03-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Interactive Data Current | Yes | ||
Entity Common Stock, Shares Outstanding (in shares) | 317,012,411 | ||
Entity Public Float | $ 7.4 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Mar. 31, 2021 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Title of 12(g) Security | Common Stock $.0001 Par Value |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 793,040 | $ 2,406 |
Prepaid expenses and other current assets | 256,251 | 18,776 |
Note receivable | 5,224,423 | |
Current assets from discontinued operations | 2,494,564 | 1,755,275 |
TOTAL CURRENT ASSETS | 3,543,855 | 7,000,880 |
Property and equipment, net | 25,022 | 37,821 |
Intangible assets, net of accumulated amortization of $43,096 and $12,287 at March 31, 2021 and 2020, respectively | 1,706,762 | 1,128,702 |
Long term assets from discontinued operations | 5,530,415 | 6,185,465 |
TOTAL ASSETS | 10,806,054 | 14,352,868 |
CURRENT LIABILITIES: | ||
Accounts payable | 1,412,459 | 1,913,049 |
Accrued interest | 493,741 | 366,865 |
Accrued liabilities | 957,946 | 813,618 |
Notes and convertible notes payable, net of unamortized discount of $296,504 and $608,580 at March 31, 2021 and 2020, respectively | 3,594,804 | 5,054,728 |
Indebtedness to related parties | 84,913 | 586,512 |
Note payable to related party | 151,923 | |
Current liabilities from discontinued operations | 2,054,585 | 1,999,062 |
TOTAL CURRENT LIABILITIES | 8,598,448 | 10,885,757 |
Convertible notes payable, net of unamortized discount of $154,590 and $0 at March 31, 2021 and 2020, respectively | 292,410 | |
Long term liabilities from discontinued operations | 3,389,124 | 3,555,605 |
TOTAL LIABILITIES | 12,279,982 | 14,441,362 |
Commitments and contingencies (Note 11) | ||
STOCKHOLDERS' EQUITY/(DEFICIT): | ||
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 315,340,411 and 275,541,602 outstanding at March 31, 2021 and 2020, respectively | 31,534 | 27,554 |
Additional paid-in capital | 102,380,770 | 97,271,157 |
Accumulated deficit | (103,886,232) | (97,387,205) |
TOTAL STOCKHOLDERS' DEFICIT | (1,473,928) | (88,494) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 10,806,054 | $ 14,352,868 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 |
Intangible assets, accumulated amortization | $ 43,096 | $ 12,287 |
Unamortized discount, current | 296,504 | 608,580 |
Unamortized discount, noncurrent | $ 154,590 | $ 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 315,340,411 | 275,541,602 |
Common stock, shares outstanding (in shares) | 315,340,411 | 275,541,602 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Sales revenue | ||
Cost of goods sold | ||
Gross profit (loss) | ||
General and administrative expenses | 2,001,617 | 5,741,514 |
LOSS FROM OPERATIONS | (2,001,617) | (5,741,514) |
OTHER INCOME (EXPENSE) | ||
Gain/(loss) on extinguishment | 467,872 | (216,954) |
Gain on settlement of accounts payable | 422,414 | |
Gain on deconsolidation | 4,393,242 | |
Interest expense | (1,285,460) | (1,109,031) |
Loss on modification of line of credit | 650,000 | |
Loss on note receivable modification | 1,895,434 | |
Debt default penalty | (286,059) | |
Other expense | 179,368 | |
Total other income/(expense) | (1,331,233) | 992,455 |
LOSS BEFORE INCOME TAXES | (3,332,850) | (4,749,059) |
Income tax expense (Note 8) | ||
LOSS FROM CONTINUING OPERATIONS | (3,332,850) | (4,749,059) |
Net loss from discontinued operations (Note 4) | (392,177) | (8,362,626) |
NET LOSS | (3,725,027) | (13,111,685) |
Loss attributable to non-controlling interest | (738,106) | |
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC. | (3,725,027) | (12,373,579) |
Net loss attributable to common stockholders of GB Sciences, Inc. | ||
Continuing operations | (3,332,850) | (4,749,059) |
Discontinued operations | (392,177) | (7,624,520) |
Net loss | $ (3,725,027) | $ (12,373,579) |
Net loss per common share – basic and diluted | ||
Continuing operations (in dollars per share) | $ (0.01) | $ (0.02) |
Discontinued operations (in dollars per share) | 0 | (0.03) |
Net loss (in dollars per share) | $ (0.01) | $ (0.05) |
Weighted average common shares outstanding - basic and diluted (in shares) | 285,190,729 | 258,450,641 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Equity/(Deficit) - USD ($) | Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Mar. 31, 2019 | 240,627,102 | |||||||||
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019 | $ (7,550) | $ (7,550) | ||||||||
Balance at Mar. 31, 2019 | $ 24,063 | $ 93,020,015 | $ (84,743,836) | $ 8,855,757 | $ 17,155,999 | |||||
Issuance of stock for debt conversion (in shares) | 7,583,333 | |||||||||
Issuance of stock for debt conversion | $ 758 | 524,242 | $ 525,000 | |||||||
Exercise of warrants for stock, net of issuance costs (in shares) | 17,563,000 | 17,563,000 | ||||||||
Exercise of warrants for stock, net of issuance costs | $ 1,756 | 1,155,971 | $ 1,157,727 | |||||||
Issuance of stock for services (in shares) | 2,100,000 | 2,100,000 | ||||||||
Issuance of stock for services | $ 210 | 213,790 | $ 214,000 | |||||||
Share based compensation expense | 287,260 | 287,260 | ||||||||
Issuance of stock for cash, net of issuance costs (in shares) | 7,668,167 | |||||||||
Issuance of stock for cash, net of issuance costs | $ 767 | 717,929 | 718,696 | |||||||
Beneficial conversion feature on notes payable | 829,737 | 829,737 | ||||||||
Contributions from non-controlling interest | 590,000 | 590,000 | ||||||||
Compensation warrants | 132,914 | 132,914 | ||||||||
Induced Dividend from Warrant Exercises | 262,240 | (262,240) | ||||||||
Induced conversions of accrued interest on notes payable | 127,059 | 127,059 | ||||||||
Deconsolidation of GB Sciences Louisiana, LLC | (8,707,651) | (8,707,651) | ||||||||
Net loss | (12,373,579) | (12,373,579) | ||||||||
Loss attributable to non-controlling interest | (738,106) | (738,106) | ||||||||
Balance (in shares) at Mar. 31, 2020 | 275,541,602 | |||||||||
Balance at Mar. 31, 2020 | $ 27,554 | 97,271,157 | (97,387,205) | (88,494) | ||||||
Issuance of stock for debt conversion (in shares) | 4,000,000 | |||||||||
Issuance of stock for debt conversion | $ 400 | 159,600 | 160,000 | |||||||
Exercise of warrants for stock, net of issuance costs (in shares) | 35,798,809 | |||||||||
Exercise of warrants for stock, net of issuance costs | $ 3,580 | 964,443 | 968,023 | |||||||
Share based compensation expense | 436,349 | 436,349 | ||||||||
Beneficial conversion feature on notes payable | 543,886 | 543,886 | ||||||||
Compensation warrants | 231,335 | 231,335 | ||||||||
Induced Dividend from Warrant Exercises | 2,774,000 | (2,774,000) | ||||||||
Net loss | (3,725,027) | (3,725,027) | ||||||||
Loss attributable to non-controlling interest | ||||||||||
Balance (in shares) at Mar. 31, 2021 | 315,340,411 | |||||||||
Balance at Mar. 31, 2021 | $ 31,534 | $ 102,380,770 | $ (103,886,232) | $ (1,473,928) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
OPERATING ACTIVITIES: | ||
Net loss | $ (3,725,027) | $ (13,111,685) |
Loss from discontinued operations | (392,177) | (8,362,626) |
Net loss from continuing operations | (3,332,850) | (4,749,059) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 47,353 | 125,502 |
Stock-based compensation | 436,349 | 287,260 |
Stock issued for services | 214,000 | |
Compensation warrants | 231,335 | 132,914 |
Amortization of debt discount and beneficial conversion feature | 776,122 | 1,150,995 |
Debt default penalty | 286,059 | |
Interest expense on conversion of notes payable | 84,354 | |
Loss on modification of line of credit | 650,000 | |
Loss/(gain) on extinguishment | (467,872) | 216,954 |
Gain on settlement of accounts payable | (422,414) | |
Loss on disposal of assets and termination of operating lease | 147,953 | |
Loss on induced conversion of note payable | 127,059 | |
Loss on note receivable modification | 1,895,434 | |
Gain on deconsolidation | (4,393,242) | |
Interest income receivable and amortization of discount on note receivable | (509,265) | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 150,137 | |
Prepaid expenses and other current assets | (237,475) | 20,932 |
Decrease in deposits and other noncurrent assets | 110,485 | |
Inventory | 83,750 | |
Accounts payable | (248,115) | 739,415 |
Accrued expenses | 166,828 | 697,429 |
Accrued interest | 549,703 | 464,279 |
Indebtedness to related parties | (501,599) | 738,435 |
Net cash used in operating activities of continuing operations | (2,066,576) | (2,264,279) |
Net cash used in operating activities of discontinued operations | (118,644) | (2,215,434) |
Net cash used in operating activities | (2,185,220) | (4,479,713) |
INVESTING ACTIVITIES: | ||
Proceeds of note receivable | 5,051,923 | |
Acquisition of intangible assets | (292,675) | (91,862) |
Net cash provided by/(used in) investing activities of continuing operations | 4,759,248 | (91,862) |
Net cash used in investing activities of discontinued operations | (103,729) | (446,922) |
Net cash provided by/(used in) investing activities | 4,655,519 | (538,784) |
FINANCING ACTIVITIES: | ||
Proceeds from issuance of common stock | 790,225 | |
Proceeds from warrant exercises | 1,075,396 | 1,274,790 |
Proceeds from convertible notes payable | 725,000 | 2,630,000 |
Proceeds from line of credit | 375,000 | |
Principal payment on notes payable and operating lease obligation | (3,156,014) | (84,869) |
Principal payment on related party note | (151,923) | |
Brokerage fees from warrant exercises and stock issuances | (107,373) | (188,593) |
Fees for issuance of convertible notes | (74,750) | (175,000) |
Net cash provided by/(used in) financing activities of continuing operations | (1,314,664) | 4,246,553 |
Net cash provided by/(used in) financing activities of discontinued operations | (161,768) | 741,655 |
Net cash provided by/(used in) financing activities | (1,476,432) | 4,988,208 |
NET CHANGE IN CASH AND CASH EQUIVALENTS | 993,867 | (30,289) |
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | 151,766 | 182,055 |
CASH AND CASH EQUIVALENTS AT END OF YEAR | 1,145,633 | 151,766 |
Less: cash and cash equivalents classified as discontinued operations | (352,593) | (149,360) |
CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS | 793,040 | 2,406 |
Cash paid for interest | 241,014 | 451,040 |
Cash paid for income tax | ||
Noncash investing and financing transactions: | ||
Accrued liabilities forgiven in connection with Wellcana Note settlement | 172,500 | |
Depreciation capitalized in inventory (discontinued operations) | 532,785 | 811,508 |
Accrued interest capitalized in convertible note principal | 223,094 | |
Property capitalized under operating leases | 182,624 | |
Patent acquisition costs capitalized in intangible assets | 319,939 | 247,646 |
Stock options issued for preparing patent applications | 168,000 | |
Stock issued upon conversion of notes payable | 160,000 | 525,000 |
Inducement dividend from warrant exercises | 2,774,000 | 262,240 |
Cumulative effect of the new lease standard | 7,550 | |
Convertible Notes Payable [Member] | ||
Noncash investing and financing transactions: | ||
Beneficial conversion feature on notes payable | $ 543,886 | $ 829,737 |
Note 1 - Background and Nature
Note 1 - Background and Nature of Operations | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB's assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Recent Developments Sale of Membership Interest in GB Sciences Louisiana, LLC On November 15, 2019, 50.01% $4,900,000 December 16, 2020, $4,900,000 (Note 13 Convertible Note Payable to Iliad Research and Trading, L.P. On April 23, 2019, 8% $2,765,000 April 22, 2020, July 14, 2020, $3,264,594 On November 20, 2020, $3,006,015 December 8, 2020, $3,006,015 $4,150,000 $3,006,015 (Note 6 Intellectual Property Portfolio On October 14th, 2020, In Silico in silico On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Planned Divestiture of Nevada Cannabis Operations On November 15, 2019, March 24, 2020, 100% $4,000,000 $4,000,000 8% (Note 14 On November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017, (Note 14 The sales of the Teco and Nopah Subsidiaries are expected to close upon the successful transfer of the Nevada cannabis cultivation and production licenses held by those subsidiaries. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 |
Note 2 - Going Concern
Note 2 - Going Concern | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | Note 2 The Company's consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $103,886,232 March 31, 2021 $5,054,593 $439,979 March 31, 2021 $3,884,877 $243,787 March 31, 2020 $2,185,220 $118,644 year ended March 31, 2021 $4,479,713 $2,215,434 year ended March 31, 2020 Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may not 19 In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 4 Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2021 2020 Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, 100% not $449,801 March 31, 2020, $1,021,067 $571,264. Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%. $4.0 $4.0M Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020 $352,274 $1,543,397, Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 158,404,020 March 31, 2021 2020 not Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 4 - Discontinued Operation
Note 4 - Discontinued Operations | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 13 (Note 14 There were no March 31, 2021 2020 March 31, 2021 2020 March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) The components of revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 ) Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2021 $24,768 $94,912 $70,144 March 31, 2021 2020 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's consolidated balance sheets at March 31, 2021 2020 March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839 Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $ 82,904 91,504 March 31, 2021 2020 March 31, 2021 2020 Leases In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company determines if an arrangement is a lease at inception and has had lease agreements for warehouses, office facilities, and equipment. As a result of the adoption of ASC 842 April 1, 2019, $182,624, $190,173 All of the Company's lease commitments previously recorded as operating leases have terminated as of March 31, 2021 March 31, 2021 March 31, 2021 2020 December 31, 2025 December 31, 2030. Operating leases are included in discontinued operations as operating lease right-of-use assets, operating lease obligations, current, and operating lease obligations, long term on the Company's balance sheets. Finance leases are included in property and equipment, finance lease obligations, current, and finance lease obligations, long term, on the Company's balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The lease costs recorded in the Company's financial statements for the years ended March 31, 2021 2020 March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653 The future minimum lease payments of lease liabilities, including the costs of the lease extension, classified as discontinued operations at March 31, 2021 Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124 |
Note 5 - Notes Payable and Line
Note 5 - Notes Payable and Line of Credit | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 5 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. $521,067 20.3% $178,933 To date, the Company has made principal payments totaling $330,555 $369,445 March 31, 2021 March 31, 2021 $13,929 March 31, 2021 $0. On August 10, 2020, (Note 14 $190,272. July 31, 2021, no no 15% 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 (Note 14 $470,000 not March 31, 2021 $485,000 $15,000. $38,767 March 31, 2021 $485,000 March 31, 2021 8% May 7, 2020 On May 7, 2020, $135,000 $15,000 $150,000 8.0% first $8,000,000 8,002,500 $0.04. $272,085 $49,525 $222,560. $150,000. March 31, 2021 $154,964 $4,964 $150,000 $154,964 October 5, 2020, 8% July 24, 2020 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019. July 24 $4,000,000 3 July 24 may (Note 14 On December 29, 2020, $975,000 three $325,000 July 24 $3,025,000. July 24 $325,000 one $4,000,000 not July 24 $650,000 two $325,000 $325,000 July 24 $50,000 $325,000 $1,025,000 March 31, 2021 $12,510 March 31, 2021 Summary of Notes Payable As of March 31, 2021 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728 |
Note 6 - Convertible Notes
Note 6 - Convertible Notes | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Convertible Debt [Text Block] | Note 6 March 2017 July 2017 In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 In July 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 $3,950,191 All notes from the March July 2017 March 31, 2021 $197,000 $1,257,000 $197,000 $0.10 788,000 three $0.10 September 30, 2023. $13,396 $33,490. 10% $46,886 $28,306 March 31, 2021 $22,412 $197,000 $44,332 March 31, 2021 $38,438 Three convertible notes totaling $1,060,000 not March 31, 2021 $208,779, $139,253 $1,060,000 $228,373 March 31, 2021 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020, 8,823,529 $0.17 100% $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 $17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019, $41,863 $0.11 The Company evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796 March 31, 2020. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 On December 29, 2020, (Note 14 November 30, 2020. During the quarter ended March 31, 2021, $160,000 $0.04 4,000,000 $1,111,863 March 31, 2021 During the year ended March 31, 2021 $477,500 $68,019 $409,481 $1,256,857 $4,000,000 no 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. $440,000 $265,000 $175,000 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 On April 22, 2020, 10%. $9,559 10% $276,500 10% On May 20, 2020, July 14, 2020, $3,264,594 15% On November 20, 2020, $3,006,015 (Note 14 December 8, 2020. December 8, 2020, December 9, 2020, $25,000 $25,000 $3,006,015 not December 16, 2020, $3,006,015 December 18, 2020, no During the year ended March 31, 2021 $379,956, $29,831 $140,833 $209,292 $25,000 $3,264,594 $209,292 $3,473,886, $467,872. December 2020 $575,000 6% On December 18, 2020, 6.0% 19 $0.05 March 31, 2021 $575,000 three $325,000 December 2021, $250,000 December 2023. $500,250, 74,750. $425,000 $347,000 At March 31, 2021 $28,496 $296,504. $135,971 $114,029. $16,354 March 31, 2021 $11,217 |
Note 7 - Property and Equipment
Note 7 - Property and Equipment | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $34,555 $541,462 year ended March 31, 2021 2020 $532,785 $811,508. $21,855 $424,501 March 31, 2021 2020 March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269 During the year ended March 31, 2020 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%. |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 8 The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company's effective tax rate was - 3.6% 0.0% March 31, 2021 2020 Income tax expense was $168,527 March 31, 2021 $48,076 $486,145 March 31, 2018 March 31, 2021 $761,509 $486,145 March 31, 2018 $154,914. $86,837 March 31, 2020 March 31, 2018 $592,982 March 31, 2020 March 31, 2021 2020 Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2021 2020 51,776,062 50,596,940 34,481,122 2025 2039. 17,294,940 March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837 The tax effects of the primary temporary differences giving rise to the Company's deferred tax assets and liabilities are as follows for the year ended March 31, 2021 and 2020 2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2021 not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2018 |
Note 9 - Capital Transactions
Note 9 - Capital Transactions | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 9 Year Ended March 31, 2021 On April 1, 2020, $0.03 $.05 35,798,809 March 31, 2021 968,023 ( 107,373 $1,591,080 During the year ended March 31, 2021 3,500,000 one $0.05 ten $168,000 During the year ended March 31, 2021 788,000 three $0.10 three $197,000 (Note 6 $13,396. On November 16, 2020, 450,000 $0.03. November 16, 2025, June 1, 2023. $4,950 $11,250 $6,300. On December 7, 2020, 3,500,000 $0.04 ten $133,000 $133,000 On December 15, 2020, 3,250,000 $0.05 ten one third one third one one third two $156,000 $62,000 March 31, 2021 $78,000 March 31, 2021 On December 15, 2020, 6,050,000 $0.05, $199,600 $250,650 $51,050. On January 2, 2021, 9,424,613 $0.01, January 2, 2024. December 11, 2020 October 1, 2023, $0.25 $1.00. $367,196 $135,861, $231,335. During the quarter ended March 31, 2021, $160,000 $0.04 4,000,000 (Note 6 On February 8, 2021, 42,705,809 December 2019 three $0.10 $1,182,920 At March 31, 2021 85,843,036 $0.01 $0.90 17,733,334 $0.11 5,883,000 $0.14 Year Ended March 31, 2020 Stock Issued for Debt Conversions During the year ended March 31, 2020, 7,583,333 On May 28, 2019, $170,000 8% February 28, 2019 ( 6 1,000,000 $0.17 $17,225 $152,775. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $127,059 two March 31, 2020. Exercise of Warrants for Stock During the year ended March 31, 2020, 17,563,000 In order to encourage the exercise of approximately 70.5 $0.65 $0.30, $0.10 July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019. 9,449,750 $850,478, $94,498. $230,025. In order to encourage the further exercise of the warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.03 $.05 December 2019. 8,113,250 $307,249, $22,566. $32,215. Issuance of Stock for Services During the year ended March 31, 2020, 2,100,000 $214,000 Warrants Outstanding Presented below is a summary of the Company's warrant activity, exclusive of warrants held by employees (see Note 10 March 31, 2021 2020 Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.030 0.035 Warrants expired/cancelled (6,390,125) 0.60 0.90 Outstanding at March 31, 2021 85,843,036 |
Note 10 - Employee Benefit Plan
Note 10 - Employee Benefit Plan | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 10 Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 4,500,000 may 2014 June 30, 2015, 8 8,500,000 April 6, 2018, 2014 2018 October 25, 2018, 8 10,000,000 2018 2,022,443 March 31, 2021 Compensation Expense For the years ended March 31, 2021 2020 436,349 287,260 $211,000 $103,472, no $78,000 March 31, 2021 Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2021 2020 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 The table below sets forth nonemployee option activity for the years ended March 31, 2021 2020 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14 Restricted stock awards No March 31, 2021 2020 |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 11 On September 18, 2017, five two five $500,000 50% $250,000 $500,000 three $750,000. August 4, 2020, first $250,000 twelve September 30, 2020, twelve August 24, 2020, $250,000 no (Note 14 An individual filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 11, 2021. On April 22, 2020, May 20, 2020, July 14, 2020, $3,264,594. December 16, 2020, $3,006,014 (Note 6 On April 22, 2020, $73,050 September 17, 2020, $25,000 $48,050. From time to time, the Company may not |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 12 As of March 31, 2021 84,913 On September 1, 2019, $20,000 9 January 2, 2021, $57,000 $114,159 $57,159, On November 16, 2020, $84,745 $78,245 $6,500 $44,192 March 31, 2021 March 31, 2020 $40,192 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 first August 4, 2020, first (Note 14 |
Note 13 - Sale of 50% Membershi
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC | 12 Months Ended |
Mar. 31, 2021 | |
GB Sciences Louisiana, LLC, Sale of Equity [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 13 50% On November 15, 2019, 50.01% $8,000,000 $8,000,000 The Wellcana note bore interest at a rate of 5% June 1, 2020 December 1, 2021. $1,389,408 17.0%, $6,610,592 November 15, 2019: November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592 Upon close of the sale on November 15, 2019, 4,393,242 As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242 On August 24, 2020, $5,224,423, $151,923, $172,500 $4,900,000 October 15, 2020, $8,000,000 $250,000 (Note 11 no $750,000 September 1, 2020, $500,000. As a result of the August 24, 2020 March 31, 2020 $5,224,423 August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 ) The Company received payments from Wellcana totaling $550,000 August September 2020, $151,923 $172,500 $4,350,000. On October 15, 2020, $4,350,000 October 15, 2020, $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020. On December 8, 2020, $250,000 $50,000 December 8, 2020, not $4,350,000 December 16, 2020, $4,150,000, The Company's statements of operations and cash flows for the year ended March 31, 2020 November 15, 2019, |
Note 14 - Sale of 100% Membersh
Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries | 12 Months Ended |
Mar. 31, 2021 | |
Nevada Subsidiaries [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 14 100% On November 15, 2019, 75% $3,000,000 $3,000,000 $470,000 (Note 5 On March 24, 2020, 100% $4,000,000 $4,000,000 8% 36 30 On July 24, 2020, 8% "July 24 July 24 $4,000,000 3 July 24 March 31, 2021 $375,000 July 24 (Note 5 On December 29, 2020, $975,000 $3,025,000, $325,000 one three not July 24 $650,000 July 24 three $325,000, $1,025,000, $4,000,000 The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. March 31, 2021 $850,000 $4,000,000 three 36 30 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017 (Note 5 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements. |
Note 15 - Concentrations
Note 15 - Concentrations | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 15 For the year ended March 31, 2021 three 18.4%, 16.7%, 13.3% March 31, 2021 two 26% 13% $513,901 March 31, 2021 March 31, 2021 $3,120,620 March 31, 2020 $3,120,620, 85%, $569,077, 15%, |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 12 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 16 On May 11, 2021, $200,000 December 31, 2021. On June 14, 2021, 1,672,000 $0.03 $50,160 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no |
Discontinued Operations, Policy [Policy Text Block] | Discontinued Operations See Note 4 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2021 2020 |
Accounts Receivable [Policy Text Block] | Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. |
Inventory, Policy [Policy Text Block] | Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first |
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] | Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, 100% not $449,801 March 31, 2020, $1,021,067 $571,264. |
Lessee, Leases [Policy Text Block] | Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%. $4.0 $4.0M |
Debt, Policy [Policy Text Block] | Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020 $352,274 $1,543,397, |
Share-based Payment Arrangement [Policy Text Block] | Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 158,404,020 March 31, 2021 2020 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 4 - Discontinued Operati_2
Note 4 - Discontinued Operations (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Disposal Groups, Including Discontinued Operations [Table Text Block] | March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 ) |
Lease, Cost [Table Text Block] | March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653 |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839 |
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] | Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124 |
Note 5 - Notes Payable and Li_2
Note 5 - Notes Payable and Line of Credit (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728 |
Note 7 - Property and Equipme_2
Note 7 - Property and Equipment (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837 The tax effects of the primary temporary differences giving rise to the Company's deferred tax assets and liabilities are as follows for the year ended March 31, 2021 and 2020 |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ - |
Note 9 - Capital Transactions (
Note 9 - Capital Transactions (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.030 0.035 Warrants expired/cancelled (6,390,125) 0.60 0.90 Outstanding at March 31, 2021 85,843,036 |
Note 10 - Employee Benefit Pl_2
Note 10 - Employee Benefit Plan (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A |
Schedule of Stock Options Roll Forward [Table Text Block] | Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14 |
Note 13 - Sale of 50% Members_2
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Tables) | 12 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Note Receivable with Imputed Interest [Table Text Block] | November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592 |
Schedule of Deconsolidation [Table Text Block] | As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242 |
Schedule of Gain (Loss) on Notes Receivable Modification [Table Text Block] | August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 ) |
Note 1 - Background and Natur_2
Note 1 - Background and Nature of Operations (Details Textual) - USD ($) | Dec. 16, 2020 | Jul. 14, 2020 | Mar. 24, 2020 | Nov. 27, 2019 | Nov. 15, 2019 | Dec. 08, 2020 | Oct. 15, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Nov. 20, 2020 | Aug. 10, 2020 | Aug. 15, 2019 | Apr. 23, 2019 | Apr. 08, 2018 | Mar. 31, 2018 |
Common Stock, Shares Authorized (in shares) | 600,000,000 | 600,000,000 | 600,000,000 | 400,000,000 | 250,000,000 | ||||||||||
Teco [Member] | |||||||||||||||
Sale of Stock, Percentage of Ownership | 100.00% | 100.00% | 100.00% | ||||||||||||
Proceeds from Collection of Notes Receivable | $ 4,000,000 | ||||||||||||||
Proceeds from Divestiture of Businesses | $ 4,000,000 | $ 4,000,000 | |||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | $ 4,000,000 | |||||||||||||
Notes Receivable, Interest Rate | 8.00% | 8.00% | |||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||
Debt Instrument, Face Amount | 2,765,000 | $ 2,765,000 | |||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member] | |||||||||||||||
Litigation Settlement, Amount Agreed to Be Paid to Offended Party | $ 3,006,015 | ||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member] | Wellcana Plus LLC [Member] | |||||||||||||||
Payments Received Under Modified Note Receivable | $ 4,150,000 | ||||||||||||||
Payments for Legal Settlements, Amount Paid Directly to Offended Party | $ 3,006,015 | ||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member] | |||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | $ 3,264,594 | |||||||||||||
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||||||||||||||
Debt Instrument, Face Amount | $ 369,445 | 369,445 | |||||||||||||
Wellcana Note [Member] | |||||||||||||||
Proceeds from Collection of Notes Receivable | $ 4,900,000 | $ 4,900,000 | |||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 7,119,857 | ||||||||||||||
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member] | |||||||||||||||
Sale of Stock, Percentage of Ownership | 50.01% | ||||||||||||||
Wellcana Plus LLC [Member] | Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member] | |||||||||||||||
Litigation Settlement, Amount Agreed to Be Paid to Offended Party, Amount Agreed By Other Counterparty to Be Paid Directly to Offended Party | $ 3,006,015 | ||||||||||||||
GB Sciences Nopah, LLC [Member] | |||||||||||||||
Sale of Interest, Percentage of Ownership | 100.00% | ||||||||||||||
Sale of Interest, Consideration to Be Received on Transaction | $ 300,000 | ||||||||||||||
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | ||||||||||||||
Sale of Interest, Consideration to Be Received on Transaction, Reduction to Balance of Debt Instrument | $ 300,000 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (103,886,232) | $ (97,387,205) |
Working Capital (Deficit) | (5,054,593) | (3,884,877) |
Net Cash Provided by (Used in) Operating Activities, Total | (2,185,220) | (4,479,713) |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | (118,644) | (2,215,434) |
Discontinued Operations [Member] | ||
Working Capital (Deficit) | $ 439,979 | $ 243,787 |
Note 3 - Basis of Presentatio_2
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) | Mar. 24, 2020 | Nov. 15, 2019 | Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2019 |
Short-term Investments, Total | $ 0 | $ 0 | |||
Research and Development Expense, Total | $ 352,274 | $ 1,543,397 | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 164,049,941 | 158,404,020 | |||
Minimum [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||||
Maximum [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 8 years | ||||
Production License [Member] | |||||
Asset Impairment Charges, Total | $ 449,801 | ||||
Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance | $ 571,264 | $ 1,021,067 | |||
Teco [Member] | |||||
Sale of Stock, Percentage of Ownership | 100.00% | 100.00% | 100.00% | ||
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows | $ 8,000,000 | ||||
Disposal Group, Including Discontinued Operation, Carrying Basis | 11,900,000 | ||||
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure | 7,300,000 | ||||
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down | $ 4,645,054 | ||||
Disposal Group, Including Discontinued Operation, Discount Rate | 17.00% | ||||
Proceeds from Collection of Notes Receivable | $ 4,000,000 |
Note 4 - Discontinued Operati_3
Note 4 - Discontinued Operations (Details Textual) - USD ($) | 12 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Apr. 01, 2019 | |
Lessee, Operating Lease, Discount Rate | 17.00% | ||
Minimum [Member] | |||
Lessee, Finance Lease, Discount Rate | 10.20% | ||
Maximum [Member] | |||
Lessee, Finance Lease, Discount Rate | 11.50% | ||
Accounting Standards Update 2016-02 [Member] | |||
Operating Lease, Right-of-Use Asset | $ 182,624 | ||
Operating Lease, Liability, Total | $ 190,173 | ||
Discontinued Operations [Member] | |||
Accounts Receivable, Allowance for Credit Loss, Recovery | $ 24,768 | ||
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total | (94,912) | ||
Accounts Receivable, Allowance for Credit Loss, Writeoff | 70,144 | ||
Deposits Assets, Noncurrent | 82,904 | $ 91,504 | |
Operating Lease, Right-of-Use Asset | 26,685 | ||
GB Sciences Louisiana, LLC [Member] | |||
Disposal Group, Including Discontinued Operation, Assets, Total | 0 | 0 | |
Disposal Group, Including Discontinued Operation, Liabilities, Total | $ 0 | $ 0 |
Note 4 - Discontinued Operati_4
Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($) | Nov. 15, 2019 | Mar. 31, 2021 | Mar. 31, 2020 |
Cash | $ 793,040 | $ 2,406 | |
Prepaid and other current assets | 256,251 | 18,776 | |
Note receivable | 5,224,423 | ||
TOTAL CURRENT ASSETS | 3,543,855 | 7,000,880 | |
Property and equipment, net | 25,022 | 37,821 | |
Intangible assets, net | 1,706,762 | 1,128,702 | |
TOTAL ASSETS | 10,806,054 | 14,352,868 | |
Accounts payable | 1,412,459 | 1,913,049 | |
Accrued interest | 493,741 | 366,865 | |
Accrued expenses | 957,946 | 813,618 | |
Notes and convertible notes payable, net | 3,594,804 | 5,054,728 | |
Indebtedness to related parties | 84,913 | 586,512 | |
Note payable to related party | 151,923 | ||
Income tax payable | 761,509 | 592,982 | |
TOTAL CURRENT LIABILITIES | 8,598,448 | 10,885,757 | |
Convertible notes payable, net | 292,410 | ||
TOTAL LIABILITIES | 12,279,982 | 14,441,362 | |
Sales revenue | |||
Cost of goods sold | |||
Gross profit (loss) | |||
General and administrative expenses | 2,001,617 | 5,741,514 | |
Gain/(loss) on extinguishment | 467,872 | (216,954) | |
Gain on settlement of accounts payable | 422,414 | ||
Gain on deconsolidation | $ 4,393,242 | 4,393,242 | |
Interest expense | (1,285,460) | (1,109,031) | |
Loss on modification of line of credit | (650,000) | ||
Loss on modification of note receivable | (1,895,434) | ||
Debt default penalty | (286,059) | ||
Total other income/(expense) | (1,331,233) | 992,455 | |
Income tax expense (Note 8) | |||
NET LOSS | (392,177) | (8,362,626) | |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||
Inventory, net | 1,689,304 | 1,445,839 | |
Finance lease obligations, current | 143,967 | ||
Finance lease obligations, long term | 3,389,124 | ||
Sales revenue | 4,110,456 | 3,689,697 | |
Cost of goods sold | (3,506,722) | (4,576,627) | |
Gross profit (loss) | 603,734 | (886,930) | |
General and administrative expenses | 276,986 | 2,034,612 | |
Loss on impairment of long-lived assets | 4,645,054 | ||
LOSS FROM OPERATIONS | 326,748 | (7,566,596) | |
Gain on settlement of accounts payable | 54,958 | ||
Interest expense | (486,481) | (694,313) | |
Other expense | (118,875) | (14,880) | |
Total other income/(expense) | (550,398) | (709,193) | |
NET LOSS BEFORE INCOME TAXES | (223,650) | (8,275,789) | |
Income tax expense (Note 8) | (168,527) | (86,837) | |
NET LOSS | (392,177) | (8,362,626) | |
Nevada Subsidiaries [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||
Sales revenue | 4,110,456 | 3,120,620 | |
Cost of goods sold | (3,506,722) | (4,002,083) | |
Gross profit (loss) | 603,734 | (881,463) | |
General and administrative expenses | 276,986 | 741,999 | |
Loss on impairment of long-lived assets | 4,645,054 | ||
LOSS FROM OPERATIONS | 326,748 | (6,268,516) | |
Gain on settlement of accounts payable | 54,958 | ||
Interest expense | (486,481) | (516,173) | |
Other expense | (118,875) | (14,880) | |
Total other income/(expense) | (550,398) | (531,053) | |
NET LOSS BEFORE INCOME TAXES | (223,650) | (6,799,569) | |
Income tax expense (Note 8) | (168,527) | (86,837) | |
NET LOSS | (392,177) | (6,886,406) | |
GB Sciences Louisiana, LLC [Member] | |||
Gain on deconsolidation | $ 4,393,242 | ||
GB Sciences Louisiana, LLC [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||
Sales revenue | 569,077 | ||
Cost of goods sold | (574,544) | ||
Gross profit (loss) | (5,467) | ||
General and administrative expenses | 1,292,613 | ||
Loss on impairment of long-lived assets | |||
LOSS FROM OPERATIONS | (1,298,080) | ||
Gain on settlement of accounts payable | |||
Interest expense | (178,140) | ||
Other expense | |||
Total other income/(expense) | (178,140) | ||
NET LOSS BEFORE INCOME TAXES | (1,476,220) | ||
Income tax expense (Note 8) | |||
NET LOSS | (1,476,220) | ||
Continuing Operations [Member] | |||
Cash | 793,040 | 2,406 | |
Accounts receivable, net | |||
Inventory, net | |||
Prepaid and other current assets | 256,251 | 18,776 | |
Note receivable | 5,224,423 | ||
TOTAL CURRENT ASSETS | 1,049,291 | 5,245,605 | |
Property and equipment, net | 25,022 | 37,821 | |
Intangible assets, net | 1,706,762 | 1,128,702 | |
Deposits and other noncurrent assets | |||
Operating lease right-of-use assets, net | |||
TOTAL ASSETS | 2,781,075 | 6,412,128 | |
Accounts payable | 1,412,459 | 1,913,049 | |
Accrued interest | 493,741 | 366,865 | |
Accrued expenses | 957,946 | 813,618 | |
Notes and convertible notes payable, net | 3,594,804 | 5,054,728 | |
Indebtedness to related parties | 84,913 | 586,512 | |
Note payable to related party | 151,923 | ||
Income tax payable | |||
Finance lease obligations, current | |||
Operating lease obligations, current | |||
TOTAL CURRENT LIABILITIES | 6,543,863 | 8,886,695 | |
Convertible notes payable, net | 292,410 | ||
Operating lease obligations, long term | |||
Finance lease obligations, long term | |||
TOTAL LIABILITIES | 6,836,273 | 8,886,695 | |
Sales revenue | |||
Cost of goods sold | |||
Gross profit (loss) | |||
General and administrative expenses | 2,001,617 | 5,741,514 | |
Loss on impairment of long-lived assets | |||
LOSS FROM OPERATIONS | (2,001,617) | (5,741,514) | |
Gain/(loss) on extinguishment | 467,872 | (216,954) | |
Gain on settlement of accounts payable | 422,414 | ||
Gain on deconsolidation | 4,393,242 | ||
Interest expense | (1,285,460) | (1,109,031) | |
Loss on modification of line of credit | (650,000) | ||
Loss on modification of note receivable | (1,895,434) | ||
Debt default penalty | (286,059) | ||
Other expense | (179,368) | ||
Total other income/(expense) | (1,331,233) | 992,455 | |
NET LOSS BEFORE INCOME TAXES | (3,332,850) | (4,749,059) | |
Income tax expense (Note 8) | |||
NET LOSS | (3,332,850) | (4,749,059) | |
Discontinued Operations [Member] | |||
Cash | 352,593 | 149,360 | |
Accounts receivable, net | 400,175 | 117,967 | |
Inventory, net | 1,689,304 | 1,445,839 | |
Prepaid and other current assets | 52,492 | 42,109 | |
Note receivable | |||
TOTAL CURRENT ASSETS | 2,494,564 | 1,755,275 | |
Property and equipment, net | 4,876,247 | 5,496,012 | |
Intangible assets, net | 571,264 | 571,264 | |
Deposits and other noncurrent assets | 82,904 | 91,504 | |
Operating lease right-of-use assets, net | 26,685 | ||
TOTAL ASSETS | 8,024,979 | 7,940,740 | |
Accounts payable | 509,477 | 646,865 | |
Accrued interest | 49,211 | 30,787 | |
Accrued expenses | 105,421 | 74,394 | |
Notes and convertible notes payable, net | 485,000 | 480,000 | |
Indebtedness to related parties | |||
Note payable to related party | |||
Income tax payable | 761,509 | 592,982 | |
Finance lease obligations, current | 143,967 | 166,769 | |
Operating lease obligations, current | 7,265 | ||
TOTAL CURRENT LIABILITIES | 2,054,585 | 1,999,062 | |
Convertible notes payable, net | |||
Operating lease obligations, long term | 22,515 | ||
Finance lease obligations, long term | 3,389,124 | 3,533,090 | |
TOTAL LIABILITIES | 5,443,709 | 5,554,667 | |
Sales revenue | 4,110,456 | 3,689,697 | |
Cost of goods sold | (3,506,722) | (4,576,627) | |
Gross profit (loss) | 603,734 | (886,930) | |
General and administrative expenses | 276,986 | 2,034,612 | |
Loss on impairment of long-lived assets | 4,645,054 | ||
LOSS FROM OPERATIONS | 326,748 | (7,566,596) | |
Gain/(loss) on extinguishment | |||
Gain on settlement of accounts payable | 54,958 | ||
Gain on deconsolidation | |||
Interest expense | (486,481) | (694,313) | |
Loss on modification of line of credit | |||
Loss on modification of note receivable | |||
Debt default penalty | |||
Other expense | (118,875) | (14,880) | |
Total other income/(expense) | (550,398) | (709,193) | |
NET LOSS BEFORE INCOME TAXES | (223,650) | (8,275,789) | |
Income tax expense (Note 8) | (168,527) | (86,837) | |
NET LOSS | (392,177) | (8,362,626) | |
Segment, Continuing and Discontinued Operations [Member] | |||
Cash | 1,145,633 | 151,766 | |
Accounts receivable, net | 400,175 | 117,967 | |
Inventory, net | 1,689,304 | 1,445,839 | |
Prepaid and other current assets | 308,743 | 60,885 | |
Note receivable | 5,224,423 | ||
TOTAL CURRENT ASSETS | 3,543,855 | 7,000,880 | |
Property and equipment, net | 4,901,269 | 5,533,833 | |
Intangible assets, net | 2,278,026 | 1,699,966 | |
Deposits and other noncurrent assets | 82,904 | 91,504 | |
Operating lease right-of-use assets, net | 26,685 | ||
TOTAL ASSETS | 10,806,054 | 14,352,868 | |
Accounts payable | 1,921,936 | 2,559,914 | |
Accrued interest | 542,952 | 397,652 | |
Accrued expenses | 1,063,367 | 888,012 | |
Notes and convertible notes payable, net | 4,079,804 | 5,534,728 | |
Indebtedness to related parties | 84,913 | 586,512 | |
Note payable to related party | 151,923 | ||
Income tax payable | 761,509 | 592,982 | |
Finance lease obligations, current | 143,967 | 166,769 | |
Operating lease obligations, current | 7,265 | ||
TOTAL CURRENT LIABILITIES | 8,598,448 | 10,885,757 | |
Convertible notes payable, net | 292,410 | ||
Operating lease obligations, long term | 22,515 | ||
Finance lease obligations, long term | 3,389,124 | 3,533,090 | |
TOTAL LIABILITIES | 12,279,982 | 14,441,362 | |
Sales revenue | 4,110,456 | 3,689,697 | |
Cost of goods sold | (3,506,722) | (4,576,627) | |
Gross profit (loss) | 603,734 | (886,930) | |
General and administrative expenses | 2,278,603 | 7,776,126 | |
Loss on impairment of long-lived assets | 4,645,054 | ||
LOSS FROM OPERATIONS | (1,674,869) | (13,308,110) | |
Gain/(loss) on extinguishment | 467,872 | (216,954) | |
Gain on settlement of accounts payable | 477,372 | ||
Gain on deconsolidation | 4,393,242 | ||
Interest expense | (1,771,941) | (1,803,344) | |
Loss on modification of line of credit | (650,000) | ||
Loss on modification of note receivable | (1,895,434) | ||
Debt default penalty | (286,059) | ||
Other expense | (118,875) | (194,248) | |
Total other income/(expense) | (1,881,631) | 283,262 | |
NET LOSS BEFORE INCOME TAXES | (3,556,500) | (13,024,848) | |
Income tax expense (Note 8) | (168,527) | (86,837) | |
NET LOSS | $ (3,725,027) | $ (13,111,685) |
Note 4 - Discontinued Operati_5
Note 4 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 |
Raw materials | $ 86,076 | $ 91,465 |
Work in progress | 743,844 | 1,166,511 |
Finished goods | 866,195 | 466,319 |
Subtotal | 1,696,115 | 1,724,295 |
Allowance to reduce inventory to NRV | (6,811) | (278,456) |
Total inventory, net | $ 1,689,304 | $ 1,445,839 |
Note 4 - Discontinued Operati_6
Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Total lease cost, discontinued operations | $ 572,935 | $ 754,653 |
Total lease cost | 572,935 | 754,653 |
Discontinued Operations [Member] | ||
Finance leases - amortization of ROU assets | 154,699 | 252,973 |
Finance leases - interest on lease liabilities | 414,993 | 426,374 |
Operating leases | 3,243 | 13,648 |
Total lease cost, discontinued operations | 572,935 | 692,995 |
Total lease cost | 572,935 | 692,995 |
Continuing Operations [Member] | General and Administrative Expense [Member] | ||
Operating leases | $ 61,658 |
Note 4 - Discontinued Operati_7
Note 4 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | Mar. 31, 2021USD ($) |
2022 | $ 544,296 |
2023 | 560,625 |
2024 | 577,444 |
2025 | 594,767 |
2026 | 612,610 |
Thereafter | 3,168,492 |
Total minimum lease payments, finance leases | 6,058,234 |
Less: Amount representing interest, finance leases | (2,525,143) |
Present value of minimum lease payments, finance leases | 3,533,091 |
Less: Current maturities of capital lease obligations, finance leases | (143,967) |
Long-term capital lease obligations, finance leases | $ 3,389,124 |
Note 5 - Notes Payable and Li_3
Note 5 - Notes Payable and Line of Credit (Details Textual) | Dec. 29, 2020USD ($) | Oct. 05, 2020USD ($) | May 07, 2020USD ($)$ / sharesshares | Oct. 23, 2017USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2021USD ($) | Aug. 10, 2020USD ($) | Jul. 24, 2020USD ($) | May 06, 2020USD ($) | Mar. 24, 2020USD ($) | Nov. 27, 2019USD ($) | Nov. 15, 2019USD ($) |
Notes Payable, Current, Total | $ 3,594,804 | $ 5,054,728 | $ 3,594,804 | $ 3,594,804 | ||||||||||
Proceeds from Lines of Credit, Total | 375,000 | |||||||||||||
Payments of Debt Issuance Costs | 74,750 | 175,000 | ||||||||||||
Interest Expense, Debt, Excluding Amortization | 84,354 | |||||||||||||
Amortization of Debt Discount (Premium) | 776,122 | 1,150,995 | ||||||||||||
Gain (Loss) on Amendment to Line of Credit | (650,000) | |||||||||||||
The July 24 Note [Member] | ||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 1,025,000 | |||||||||||||
Gain (Loss) on Amendment to Line of Credit | (650,000) | |||||||||||||
Repriced Preexisting Warrants with Convertible Debt Issuance [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 8,002,500 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.04 | |||||||||||||
Warrants and Rights Outstanding | $ 272,085 | $ 49,525 | ||||||||||||
Fair Value Adjustment of Warrants | $ 222,560 | |||||||||||||
Line of Credit [Member] | ||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | |||||||||||||
Proceeds from Lines of Credit, Total | 485,000 | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Increased | 15,000 | |||||||||||||
Interest Payable | 38,767 | 38,767 | 38,767 | |||||||||||
Long-term Line of Credit, Total | 485,000 | 485,000 | 485,000 | |||||||||||
Teco [Member] | ||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | $ 4,000,000 | ||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||
Teco [Member] | The July 24 Note [Member] | ||||||||||||||
Interest and Debt Expense, Total | 12,510 | |||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 1,025,000 | 1,025,000 | 1,025,000 | ||||||||||
Increase (Decrease) in Notes Receivable, Current | 975,000 | |||||||||||||
Notes Receivable, Maximum Allowed Prepayments On Note | 325,000 | |||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | 4,000,000 | |||||||||||||
Gain (Loss) on Amendment to Line of Credit | $ (650,000) | |||||||||||||
Notes Receivable, Additional Advances | 50,000 | |||||||||||||
The July 24 Note [Member] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||
The July 24 Note [Member] | Revolving Credit Facility [Member] | ||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 500,000 | |||||||||||||
The July 24 Note [Member] | Teco [Member] | ||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | |||||||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | |||||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | ||||||||||||
Debt Instrument, Face Amount | $ 700,000 | |||||||||||||
Debt Instrument, Term (Year) | 3 years | |||||||||||||
Debt Instrument, Present Value | $ 521,067 | |||||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | |||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 178,933 | 0 | 0 | 0 | ||||||||||
Repayments of Debt | 330,555 | |||||||||||||
Notes Payable, Current, Total | 369,445 | 369,445 | 369,445 | |||||||||||
Interest Expense, Debt, Total | 13,929 | |||||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member] | ||||||||||||||
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition | $ 190,272 | |||||||||||||
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition | 15.00% | |||||||||||||
Convertible Debt [Member] | ||||||||||||||
Interest Expense, Debt, Total | 208,779 | |||||||||||||
Interest Payable | 228,373 | $ 228,373 | $ 228,373 | |||||||||||
Amortization of Debt Discount (Premium) | 139,253 | |||||||||||||
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||
Debt Instrument, Face Amount | $ 150,000 | |||||||||||||
Debt Instrument, Unamortized Discount, Total | 150,000 | |||||||||||||
Proceeds from Issuance of Long-term Debt, Net | 135,000 | |||||||||||||
Payments of Debt Issuance Costs | 15,000 | |||||||||||||
Repayments of Long-term Debt, Total | $ 8,000,000 | |||||||||||||
Interest and Debt Expense, Total | $ 154,964 | 154,964 | ||||||||||||
Interest Expense, Debt, Excluding Amortization | 4,964 | |||||||||||||
Amortization of Debt Discount (Premium) | $ 150,000 | |||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | ||||||||||||||
Payments to Acquire License | $ 500,000 | |||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member] | ||||||||||||||
Ownership of Licence | 100.00% | |||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member] | ||||||||||||||
Ownership of Licence | 100.00% |
Note 5 - Notes Payable and Li_4
Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 | Apr. 23, 2019 | Oct. 23, 2017 |
Discount, short-term notes payable | $ (296,504) | $ (608,580) | ||
Discount, long-term notes payable | (154,590) | 0 | ||
Promissory Note [Member] | ||||
Total short term notes and convertible notes payable classified as continuing operations | 447,000 | |||
Discount, long-term notes payable | (154,590) | |||
Carrying Value, long-term notes payable | 292,410 | |||
Face Value, long-term notes payable | 447,000 | |||
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | ||||
Face Value, short-term notes payable | $ 700,000 | |||
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member] | ||||
Face Value, short-term notes payable | 197,000 | |||
Discount, long-term notes payable | (40,561) | |||
Carrying Value, long-term notes payable | 156,439 | |||
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member] | ||||
Face Value, short-term notes payable | 250,000 | |||
Discount, long-term notes payable | (114,029) | |||
Carrying Value, long-term notes payable | 135,971 | |||
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | ||||
Face Value, short-term notes payable | 369,445 | 369,445 | ||
Discount, short-term notes payable | (13,929) | |||
Carrying Value, short-term notes payable | 369,445 | 355,516 | ||
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member] | ||||
Face Value, short-term notes payable | 1,060,000 | 1,257,000 | ||
Discount, short-term notes payable | (155,340) | |||
Carrying Value, short-term notes payable | 1,060,000 | 1,101,660 | ||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | ||||
Face Value, short-term notes payable | 2,765,000 | $ 2,765,000 | ||
Discount, short-term notes payable | (29,830) | |||
Carrying Value, short-term notes payable | 2,735,170 | |||
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member] | ||||
Face Value, short-term notes payable | 325,000 | |||
Discount, short-term notes payable | (296,504) | |||
Carrying Value, short-term notes payable | 28,496 | |||
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member] | ||||
Face Value, short-term notes payable | 485,000 | 480,000 | ||
Discount, short-term notes payable | ||||
Carrying Value, short-term notes payable | 485,000 | 480,000 | ||
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member] | ||||
Face Value, short-term notes payable | 1,025,000 | |||
Discount, short-term notes payable | ||||
Carrying Value, short-term notes payable | 1,025,000 | |||
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | ||||
Face Value, short-term notes payable | 1,111,863 | 1,271,863 | ||
Discount, short-term notes payable | (409,481) | |||
Carrying Value, short-term notes payable | 1,111,863 | 862,382 | ||
Promissory Note [Member] | ||||
Face Value, short-term notes payable | 4,376,308 | 6,143,308 | ||
Discount, short-term notes payable | (296,504) | (608,580) | ||
Carrying Value, short-term notes payable | 4,079,804 | 5,534,728 | ||
Less: Notes payable classified as discontinued operations, face value | (485,000) | (480,000) | ||
Less: Notes payable classified as discontinued operations, discount | ||||
Less: Notes payable classified as discontinued operations, carrying value | (485,000) | (480,000) | ||
Total short term notes and convertible notes payable classified as continuing operations | 3,891,308 | 5,663,308 | ||
Total short term notes and convertible notes payable classified as continuing operations | (296,504) | (608,580) | ||
Total short term notes and convertible notes payable classified as continuing operations | 3,594,804 | 5,054,728 | ||
Face Value, long-term notes payable | $ 3,891,308 | $ 5,663,308 |
Note 6 - Convertible Notes (Det
Note 6 - Convertible Notes (Details Textual) | Dec. 16, 2020USD ($) | Jul. 14, 2020USD ($) | Apr. 22, 2020USD ($) | Dec. 16, 2019USD ($)$ / sharesshares | Nov. 27, 2019USD ($)$ / shares | Nov. 18, 2019USD ($)$ / sharesshares | Oct. 30, 2019USD ($)$ / sharesshares | Oct. 23, 2019USD ($)$ / shares | Aug. 01, 2019USD ($)$ / sharesshares | Jul. 12, 2019USD ($)$ / shares | May 28, 2019USD ($)$ / sharesshares | Apr. 23, 2019USD ($)$ / shares | Feb. 28, 2019USD ($)$ / shares | Jul. 31, 2017USD ($)$ / shares | Mar. 31, 2017USD ($)$ / shares | Mar. 31, 2021USD ($)$ / sharesshares | May 31, 2017USD ($)$ / sharesshares | Mar. 31, 2021USD ($)$ / shares | Dec. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2021USD ($)$ / sharesshares | Mar. 31, 2020USD ($)shares | Dec. 18, 2020$ / shares | Dec. 09, 2020USD ($) | Nov. 20, 2020USD ($) | Dec. 31, 2019USD ($) |
Class of Warrant or Right, Issued During Period (in shares) | shares | 43,493,809 | 7,622,780 | |||||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 776,122 | $ 1,150,995 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 7,583,333 | ||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | 467,872 | $ (216,954) | |||||||||||||||||||||||
Interest Expense, Debt, Excluding Amortization | 84,354 | ||||||||||||||||||||||||
Induced Conversion of Convertible Debt Expense | 127,059 | ||||||||||||||||||||||||
Proceeds from Convertible Debt | 725,000 | 2,630,000 | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | $ 296,504 | $ 296,504 | 296,504 | 608,580 | |||||||||||||||||||||
Convertible Notes Payable, Noncurrent | 292,410 | 292,410 | 292,410 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 154,590 | 154,590 | 154,590 | 0 | |||||||||||||||||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | |||||||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 15.00% | ||||||||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | ||||||||||||||||||||||||
Litigation Settlement, Amount Final Settlement | $ 3,006,015 | $ 3,006,015 | |||||||||||||||||||||||
Litigation Settlement, One Time Required Payment | 25,000 | ||||||||||||||||||||||||
Litigation Settlement, Weekly Required Payment | $ 25,000 | ||||||||||||||||||||||||
Litigation Settlement, Payment | $ 3,006,015 | ||||||||||||||||||||||||
Judgment Settlement Agreement [Member] | Judicial Ruling [Member] | |||||||||||||||||||||||||
Litigation Settlement, Expense | 25,000 | ||||||||||||||||||||||||
Teco [Member] | |||||||||||||||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | 4,000,000 | 4,000,000 | 4,000,000 | ||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||
Debt Instrument, Extended Amount | 197,000 | 197,000 | 197,000 | ||||||||||||||||||||||
Interest Expense, Debt, Total | 208,779 | ||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 139,253 | ||||||||||||||||||||||||
Interest Payable | 228,373 | 228,373 | 228,373 | ||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | $ 1,060,000 | $ 1,060,000 | $ 1,060,000 | ||||||||||||||||||||||
Warrants Issued in March 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.60 | $ 0.60 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | 3 years | |||||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 8,000,000 | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||||||||
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | shares | 788,000 | ||||||||||||||||||||||||
Warrants Related to July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.65 | $ 0.60 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 28,804,000 | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||||||||
Warrants Issued in September 30, 2023, Convertible Note Offering [Member] | |||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.10 | $ 0.10 | $ 0.10 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | 3 years | 3 years | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 13,396 | $ 13,396 | $ 13,396 | ||||||||||||||||||||||
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 46,886 | 46,886 | 46,886 | ||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 33,490 | ||||||||||||||||||||||||
Interest Expense, Debt, Total | 28,306 | ||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 22,412 | ||||||||||||||||||||||||
Interest Payable | 44,332 | 44,332 | 44,332 | ||||||||||||||||||||||
Interest Payable, Accrued Prior to Extinguishments | 38,438 | 38,438 | 38,438 | ||||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | ||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.05 | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 74,750 | 74,750 | 74,750 | ||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 347,000 | ||||||||||||||||||||||||
Interest Expense, Debt, Total | 16,354 | ||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 11,217 | ||||||||||||||||||||||||
Convertible Notes Payable, Current | 28,496 | 28,496 | 28,496 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 296,504 | 296,504 | 296,504 | ||||||||||||||||||||||
Convertible Notes Payable, Noncurrent | 135,971 | 135,971 | 135,971 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 114,029 | 114,029 | 114,029 | ||||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount | 575,000 | 575,000 | 575,000 | ||||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount | 325,000 | 325,000 | 325,000 | ||||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | 250,000 | 250,000 | ||||||||||||||||||||||
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 425,000 | $ 425,000 | 425,000 | ||||||||||||||||||||||
Proceeds from Convertible Debt | 500,250 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 543,886 | 829,737 | |||||||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | ||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | ||||||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 1,933,693 | ||||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 904,690 | ||||||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 1,029,003 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 8,000,000 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 7,201,000 | ||||||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | 3 years | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 7,092,796 | ||||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 3,142,605 | ||||||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 3,950,191 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 28,804,000 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.10 | $ 0.10 | $ 0.10 | ||||||||||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | $ 197,000 | $ 197,000 | ||||||||||||||||||||||
Convertible Notes Payable, Total | 1,257,000 | 1,257,000 | 1,257,000 | ||||||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.0375 | $ 0.06 | $ 0.17 | ||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,765,000 | 2,765,000 | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 265,000 | ||||||||||||||||||||||||
Interest Expense, Debt, Total | 209,292 | 379,956 | |||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 29,831 | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | $ 75,000 | 125,000 | ||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 1,333,333 | 1,250,000 | |||||||||||||||||||||||
Short-term Debt, Total | 2,735,170 | ||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | 467,872 | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 440,000 | ||||||||||||||||||||||||
Payments for Brokerage Fees | $ 175,000 | ||||||||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 62,353 | $ 64,706 | 127,059 | ||||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 10.00% | ||||||||||||||||||||||||
Debt Instrument, Debt Default, Interest Expense | $ 9,559 | ||||||||||||||||||||||||
Debt Instrument, Debt Default, Principal Expense | $ 276,500 | ||||||||||||||||||||||||
Debt Instrument, Debt Default, Increase in Principal Amount, Percent | 10.00% | ||||||||||||||||||||||||
Interest Expense, Debt, Pre-judgment Interest | 140,833 | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 29,830 | ||||||||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member] | |||||||||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | 3,264,594 | |||||||||||||||||||||||
Litigation Settlement, Amount Including Interest Expense | 3,473,886 | 3,473,886 | 3,473,886 | ||||||||||||||||||||||
Promissory Note [Member] | |||||||||||||||||||||||||
Debt Instrument, Face Amount | 4,376,308 | 4,376,308 | 4,376,308 | 6,143,308 | |||||||||||||||||||||
Short-term Debt, Total | 4,079,804 | 4,079,804 | 4,079,804 | 5,534,728 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 296,504 | 296,504 | 296,504 | 608,580 | |||||||||||||||||||||
Promissory Note [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | ||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | 8.00% | ||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 57,551 | $ 9,579 | $ 584,842 | ||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 92,796 | $ 133,806 | $ 176,471 | ||||||||||||||||||||||
Interest Expense, Debt, Total | 584,842 | 477,500 | |||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 57,551 | 409,481 | |||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 120,000 | 110,000 | 160,000 | 125,000 | |||||||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | (62,449) | $ 30,000 | (100,421) | 100,000 | |||||||||||||||||||||
Short-term Debt, Total | 1,271,863 | 1,361,863 | $ 1,269,067 | $ 1,361,863 | 1,338,057 | 1,111,863 | 1,111,863 | 1,111,863 | $ 687,021 | ||||||||||||||||
Proceeds from Related Party Debt | 100,000 | ||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 41,863 | ||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 0 | $ (124,158) | $ (92,796) | ||||||||||||||||||||||
Long-term Debt, Gross | $ 687,021 | ||||||||||||||||||||||||
Interest Expense, Debt, Excluding Amortization | 68,019 | ||||||||||||||||||||||||
Long Term Debt Including Interest | $ 1,256,857 | $ 1,256,857 | $ 1,256,857 | ||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member] | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 17,225 | ||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 170,000 | ||||||||||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | (152,775) | ||||||||||||||||||||||||
Short-term Debt, Total | $ 1,330,000 | ||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member] | |||||||||||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 100.00% | ||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 8,823,529 | ||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.04 | $ 0.04 | $ 0.08 | $ 0.11 | $ 0.11 | $ 0.17 | $ 0.04 | $ 0.04 | $ 0.04 | ||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 3,000,000 | 1,000,000 | 4,000,000 | ||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member] | |||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.17 | ||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 1,000,000 |
Note 7 - Property and Equipme_3
Note 7 - Property and Equipment (Details Textual) - USD ($) | Mar. 24, 2020 | Nov. 15, 2019 | Mar. 31, 2021 | Mar. 31, 2020 |
Depreciation, Total | $ 34,555 | $ 541,462 | ||
Depreciation, Capitalized to Inventory | 532,785 | $ 811,508 | ||
Teco [Member] | ||||
Sale of Stock, Percentage of Ownership | 100.00% | 100.00% | 100.00% | |
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows | $ 8,000,000 | |||
Disposal Group, Including Discontinued Operation, Carrying Basis | 11,900,000 | |||
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure | 7,300,000 | |||
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down | $ 4,645,054 | |||
Disposal Group, Including Discontinued Operation, Discount Rate | 17.00% | |||
Discontinued Operations [Member] | ||||
Depreciation, Total | 21,855 | $ 424,501 | ||
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down | $ 4,645,054 |
Note 7 - Property and Equipme_4
Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 |
Property and Equipment, Gross | $ 771,379 | |
Property and Equipment, Gross, Including Discontinued Operations | 6,200,097 | |
Less accumulated depreciation and amortization | (746,357) | |
Less accumulated depreciation and amortization, Including Discontinued Operations | (1,298,828) | |
Property and Equipment, Net | 25,022 | $ 37,821 |
Property and Equipment, Net, Including Discontinued Operations | 4,901,269 | |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | 5,428,717 | |
Less accumulated depreciation and amortization, Discontinued Operations | (552,471) | |
Property and Equipment, Net, Discontinued Operations | 4,876,247 | |
Furniture and Fixtures [Member] | ||
Property and Equipment, Gross | ||
Property and Equipment, Gross, Including Discontinued Operations | ||
Furniture and Fixtures [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | ||
Computer Equipment [Member] | ||
Property and Equipment, Gross | 151,748 | |
Property and Equipment, Gross, Including Discontinued Operations | 151,748 | |
Computer Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | ||
Machinery and Equipment [Member] | ||
Property and Equipment, Gross | 619,631 | |
Property and Equipment, Gross, Including Discontinued Operations | 908,666 | |
Machinery and Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | 289,035 | |
Leaseholds and Leasehold Improvements [Member] | ||
Property and Equipment, Gross | ||
Property and Equipment, Gross, Including Discontinued Operations | 3,455,600 | |
Leaseholds and Leasehold Improvements [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | 3,455,600 | |
Construction in Progress [Member] | ||
Property and Equipment, Gross | ||
Property and Equipment, Gross, Including Discontinued Operations | 21,069 | |
Construction in Progress [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | 21,069 | |
Finance Lease Right-of-use Asset [Member] | ||
Property and Equipment, Gross | ||
Property and Equipment, Gross, Including Discontinued Operations | 1,663,013 | |
Finance Lease Right-of-use Asset [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | ||
Property and Equipment, Gross, Discontinued Operations | $ 1,663,013 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Effective Income Tax Rate Reconciliation, Percent, Total | (3.60%) | 0.00% |
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations, Total | $ 168,527 | $ 86,837 |
Income Tax Reconciliation, Prior Year Tax Penalties | 48,076 | |
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount | 486,145 | |
Taxes Payable, Current, Total | 761,509 | 592,982 |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total | 154,914 | |
Operating Loss Carryforwards, Total | 51,776,062 | 50,596,940 |
Operating Loss Carryforwards, Subject to Expiration | $ 34,481,122 | |
Operating Loss Carryforwards, Not Subject to Expiration | $ 17,294,940 |
Note 8 - Income Taxes - Reconci
Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Tax benefit computed at U.S. statutory rates | $ (697,040) | $ (2,178,478) |
IRC Section 280E | 173,045 | 202,877 |
Other permanent items | 14,407 | 22,948 |
Change in valuation allowance | 26,720 | 1,952,653 |
Adjustments to valuation of deferred tax assets | 603,319 | |
Total provision for income taxes | 120,451 | |
Penalties and interest on prior year tax liabilities | 48,076 | 86,837 |
Total income tax expense | $ 168,527 | $ 86,837 |
Note 8 - Income Taxes - Deferre
Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) | Mar. 31, 2021 | Mar. 31, 2020 |
Stock based compensation | $ 3,131,344 | $ 2,943,816 |
Net operating loss carryforward | 10,460,788 | 10,625,357 |
Impairment of long-lived assets | 975,461 | 975,461 |
Depreciation and Amortization expense | (458,938) | (324,707) |
Other temporary items | 220,795 | 136,243 |
Total deferred tax assets | 14,329,450 | 14,356,170 |
Less valuation allowance | (14,329,450) | (14,356,170) |
Net deferred tax asset |
Note 9 - Capital Transactions_2
Note 9 - Capital Transactions (Details Textual) - USD ($) | Jan. 02, 2021 | Dec. 15, 2020 | Dec. 07, 2020 | Nov. 16, 2020 | Dec. 16, 2019 | Nov. 27, 2019 | Nov. 18, 2019 | Oct. 30, 2019 | Aug. 01, 2019 | Jul. 12, 2019 | May 28, 2019 | Dec. 31, 2019 | Mar. 31, 2021 | Jul. 11, 2019 | Mar. 31, 2021 | Mar. 31, 2020 | Feb. 08, 2021 | Jan. 01, 2021 | Apr. 01, 2020 | Oct. 23, 2019 | Apr. 23, 2019 | Mar. 31, 2019 | Feb. 28, 2019 |
Proceeds from Warrant Exercises | $ 1,075,396 | $ 1,274,790 | |||||||||||||||||||||
Induced Dividend from Warrant Exercises | |||||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 43,493,809 | 7,622,780 | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 85,843,036 | 85,843,036 | 84,538,161 | 99,790,989 | |||||||||||||||||||
Class of Warrant or Right, Expense | $ 211,000 | $ 103,472 | |||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 7,583,333 | ||||||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 127,059 | ||||||||||||||||||||||
Exercise of Warrants for Stock, Shares (in shares) | 17,563,000 | ||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 2,100,000 | ||||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 214,000 | ||||||||||||||||||||||
Share-based Payment Arrangement, Employee [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 6,750,000 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.045 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 17,733,334 | 17,733,334 | 10,983,334 | 12,583,334 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 0.11 | $ 0.11 | $ 0.28 | $ 0.28 | |||||||||||||||||||
Share-based Payment Arrangement, Nonemployee [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 3,500,000 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 5,883,000 | 5,883,000 | 2,383,000 | 2,383,000 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 0.14 | $ 0.14 | $ 0.27 | $ 0.27 | |||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||
Induced Dividend from Warrant Exercises | |||||||||||||||||||||||
Exercise of Warrants for Stock, Shares (in shares) | 35,798,809 | 17,563,000 | |||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 2,100,000 | ||||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 210 | ||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | $ 197,000 | |||||||||||||||||||||
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member] | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 46,886 | $ 46,886 | |||||||||||||||||||||
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member] | |||||||||||||||||||||||
Debt Instrument, Extension Period (Year) | 3 years | ||||||||||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | $ 197,000 | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.10 | $ 0.10 | |||||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | $ 75,000 | 125,000 | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.0375 | $ 0.06 | $ 0.17 | ||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 1,333,333 | 1,250,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 265,000 | ||||||||||||||||||||||
Short-term Debt, Total | 2,735,170 | ||||||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 62,353 | $ 64,706 | 127,059 | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 120,000 | $ 110,000 | $ 160,000 | 125,000 | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | 8.00% | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 57,551 | 9,579 | $ 584,842 | ||||||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | (62,449) | $ 30,000 | (100,421) | $ 100,000 | |||||||||||||||||||
Short-term Debt, Total | $ 1,271,863 | $ 1,361,863 | $ 1,361,863 | $ 1,338,057 | $ 687,021 | $ 1,111,863 | $ 1,111,863 | $ 1,269,067 | |||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member] | |||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 170,000 | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 17,225 | ||||||||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | (152,775) | ||||||||||||||||||||||
Short-term Debt, Total | $ 1,330,000 | ||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.04 | $ 0.04 | $ 0.11 | $ 0.11 | $ 0.04 | $ 0.04 | $ 0.08 | $ 0.17 | |||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 3,000,000 | 1,000,000 | 4,000,000 | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member] | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.17 | ||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 1,000,000 | ||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ 51,050 | $ 436,349 | $ 287,260 | ||||||||||||||||||||
Scientist and Researcher [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 3,500,000 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 168,000 | ||||||||||||||||||||||
Scientist and Researcher [Member] | Share-based Payment Arrangement, Option [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||||||||||
Former Director [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.03 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 450,000 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value | $ 4,950 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value | 11,250 | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ 6,300 | ||||||||||||||||||||||
Employees and Directors [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 3,250,000 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 156,000 | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense | 62,000 | ||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 78,000 | $ 78,000 | |||||||||||||||||||||
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||||||||||
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 33.33% | ||||||||||||||||||||||
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 33.33% | ||||||||||||||||||||||
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Three [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 33.33% | ||||||||||||||||||||||
Current Employees [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.05 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 6,050,000 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value | $ 199,600 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value | $ 250,650 | ||||||||||||||||||||||
Warrants Issued to Investors in Private Placements [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercises in Period (in shares) | 9,449,750 | 8,113,250 | 35,798,809 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ 850,478 | $ 307,249 | $ 968,023 | ||||||||||||||||||||
Brokerage Fees for Issuance of Common Stock and Warrants | 94,498 | 22,566 | 107,373 | ||||||||||||||||||||
Induced Dividend from Warrant Exercises | $ 32,215 | $ 1,591,080 | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 70,500,000 | ||||||||||||||||||||||
Class of Warrant or Right, Temporarily Reduced Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | ||||||||||||||||||||||
Inducement Dividend, Exercise of Warrants | $ 230,025 | ||||||||||||||||||||||
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.03 | 0.65 | $ 0.03 | ||||||||||||||||||||
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.05 | $ 0.30 | $ 0.05 | ||||||||||||||||||||
Convertible Warrant [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | $ 0.10 | |||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 788,000 | ||||||||||||||||||||||
Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year) | 3 years | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 13,396 | $ 13,396 | |||||||||||||||||||||
Employees and Director Warrants [Member] | Employees and Directors [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.04 | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 133,000 | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ 133,000 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,500,000 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | ||||||||||||||||||||||
Compensation Warrants Issued to Brokers [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 367,196 | $ 135,861 | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 9,424,613 | ||||||||||||||||||||||
Class of Warrant or Right, Expense | $ 231,335 | ||||||||||||||||||||||
Compensation Warrants Issued to Brokers [Member] | Minimum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.25 | ||||||||||||||||||||||
Compensation Warrants Issued to Brokers [Member] | Maximum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1 | ||||||||||||||||||||||
Replacement Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,182,920 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 42,705,809 | ||||||||||||||||||||||
Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 85,843,036 | 85,843,036 | |||||||||||||||||||||
Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | $ 0.01 | |||||||||||||||||||||
Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.90 | $ 0.90 |
Note 9 - Capital Transactions -
Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Outstanding (in shares) | 84,538,161 | 99,790,989 |
Warrants issued (in shares) | 43,493,809 | 7,622,780 |
Warrants issued, exercise price (in dollars per share) | $ 0.10 | $ 0.30 |
Warrants exercised (in shares) | (35,798,809) | (17,563,000) |
Warrants expired/cancelled (in shares) | (6,390,125) | (5,312,608) |
Outstanding (in shares) | 85,843,036 | 84,538,161 |
Minimum [Member] | ||
Warrants exercised, exercise price (in dollars per share) | $ 0.03 | $ 0.035 |
Warrants expired/cancelled, exercise price (in dollars per share) | 0.60 | 0.50 |
Maximum [Member] | ||
Warrants exercised, exercise price (in dollars per share) | 0.035 | 0.10 |
Warrants expired/cancelled, exercise price (in dollars per share) | $ 0.90 | $ 2 |
Note 10 - Employee Benefit Pl_3
Note 10 - Employee Benefit Plan (Details Textual) - USD ($) | Dec. 15, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Oct. 25, 2018 | Jun. 30, 2015 | Feb. 06, 2008 |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 2,022,443 | |||||
Class of Warrant or Right, Expense | $ 211,000 | $ 103,472 | ||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 78,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 0 | 0 | ||||
Restricted Stock [Member] | ||||||
Share-based Payment Arrangement, Expense | $ 0 | $ 0 | ||||
Share-based Payment Arrangement, Option [Member] | ||||||
Share-based Payment Arrangement, Expense | $ 51,050 | $ 436,349 | $ 287,260 | |||
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 4,500,000 | |||||
The 2014 Equity Compensation Plan [Member] | Share-based Payment Arrangement, Option [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 8,500,000 | |||||
GB Sciences, Inc 2018 Stock Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 10,000,000 |
Note 10 - Employee Benefit Pl_4
Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-based Payment Arrangement, Option [Member] | 12 Months Ended |
Mar. 31, 2021 | |
Weighted-average volatility | 127.00% |
Expected term (in years) (Year) | 10 years |
Risk-free interest rate | 0.93% |
Note 10 - Employee Benefit Pl_5
Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($) | 12 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2019 | |
Share-based Payment Arrangement, Employee [Member] | |||
Outstanding, options (in shares) | 10,983,334 | 12,583,334 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.28 | $ 0.28 | |
Outstanding, weighted average remaining contractual life (Year) | 6 years 292 days | 6 years 7 days | 7 years 65 days |
Outstanding, aggregate intrinsic value | $ 172,000 | $ 43,000 | |
Granted, options (in shares) | 6,750,000 | ||
Granted, weighted average exercise price (in dollars per share) | $ 0.045 | ||
Exercised, options (in shares) | |||
Exercised, weighted average exercise price (in dollars per share) | |||
Forfeited, options (in shares) | (1,600,000) | ||
Forfeited, weighted average exercise price (in dollars per share) | $ 0.27 | ||
Outstanding, options (in shares) | 17,733,334 | 10,983,334 | 12,583,334 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.11 | $ 0.28 | $ 0.28 |
Fully vested and expected to vest, options (in shares) | 17,733,334 | ||
Fully vested and expected to vest, weighted average exercise price (in dollars per share) | $ 0.11 | ||
Exercisable, options (in shares) | 15,566,668 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 0.12 | ||
Share-based Payment Arrangement, Nonemployee [Member] | |||
Outstanding, options (in shares) | 2,383,000 | 2,383,000 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.27 | $ 0.27 | |
Outstanding, weighted average remaining contractual life (Year) | 8 years 40 days | 6 years 273 days | 7 years 277 days |
Outstanding, aggregate intrinsic value | $ 35,000 | $ 492,250 | |
Granted, options (in shares) | 3,500,000 | ||
Granted, weighted average exercise price (in dollars per share) | $ 0.05 | ||
Exercised, options (in shares) | |||
Exercised, weighted average exercise price (in dollars per share) | |||
Forfeited, options (in shares) | |||
Forfeited, weighted average exercise price (in dollars per share) | |||
Outstanding, options (in shares) | 5,883,000 | 2,383,000 | 2,383,000 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.14 | $ 0.27 | $ 0.27 |
Fully vested and expected to vest, options (in shares) | 5,883,000 | ||
Fully vested and expected to vest, weighted average exercise price (in dollars per share) | $ 0.14 | ||
Exercisable, options (in shares) | 5,883,000 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 0.14 |
Note 11 - Commitments and Con_2
Note 11 - Commitments and Contingencies (Details Textual) | Dec. 16, 2020USD ($) | Sep. 17, 2020USD ($) | Aug. 24, 2020USD ($) | Jul. 14, 2020USD ($) | Apr. 22, 2020USD ($) | Sep. 18, 2017USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2021USD ($) |
Research and Development Expense, Total | $ 352,274 | $ 1,543,397 | |||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | |||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | ||||||||
Litigation Settlement, Payment | $ 3,006,015 | ||||||||
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member] | |||||||||
Loss Contingency, Damages Sought, Value | $ 73,050 | ||||||||
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member] | |||||||||
Payments for Legal Settlements | $ 25,000 | ||||||||
Reduction in Cost Basis of Fixed Asset Related to Litigation | $ 48,050 | ||||||||
Agreement With Louisiana State University AgCenter [Member] | |||||||||
Term of Agreement (Year) | 5 years | 3 years | |||||||
Option to Renew Agreement, Amount | 2 | ||||||||
Term of Agreement, Renewal (Year) | 5 years | ||||||||
Research and Development Expense, Total | $ 500,000 | $ 250,000 | $ 750,000 | ||||||
Annual Research Contributions | $ 250,000 |
Note 12 - Related Party Trans_2
Note 12 - Related Party Transactions (Details Textual) - USD ($) | Jan. 02, 2021 | Nov. 16, 2020 | Mar. 31, 2021 | Mar. 31, 2020 |
Notes Payable, Related Parties, Current | $ 151,923 | |||
Leslie Bocskor [Member] | ||||
Due to Related Parties, Total | $ 78,245 | |||
Payments for Postemployment Benefits | 6,500 | |||
Salary and Wage, Excluding Cost of Good and Service Sold, Total | 44,192 | $ 40,192 | ||
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member] | ||||
Related Party Transaction, Expenses from Transactions with Related Party | 20,000 | |||
Related Party Transaction, Amounts of Transaction | $ 84,745 | |||
Ksenia Griswold [Member] | Unpaid Severance Compensation [Member] | ||||
Due to Related Parties, Total | $ 114,159 | |||
Related Party Transaction, Amounts of Transaction | 57,000 | |||
Other Income | $ 57,159 | |||
John Davis [Member] | ||||
Notes Payable, Related Parties, Current | 151,923 | |||
Officers and Directors [Member] | ||||
Due to Related Parties, Total | $ 84,913 |
Note 13 - Sale of 50% Members_3
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($) | Dec. 16, 2020 | Dec. 08, 2020 | Oct. 29, 2020 | Nov. 15, 2019 | Sep. 30, 2020 | Aug. 31, 2020 | Oct. 15, 2020 | Oct. 15, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Aug. 24, 2020 | Aug. 23, 2020 |
Receivable with Imputed Interest, Discount | $ 1,389,408 | ||||||||||||
Deconsolidation, Gain (Loss), Amount | 4,393,242 | $ 4,393,242 | |||||||||||
Repayments of Related Party Debt | $ 151,923 | ||||||||||||
Wellcana Note [Member] | |||||||||||||
Note Receivable, Interest Rate | 5.00% | ||||||||||||
Receivable with Imputed Interest, Discount | $ 1,389,408 | ||||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 17.00% | ||||||||||||
Receivable with Imputed Interest, Net Amount, Total | 6,610,592 | $ 6,610,592 | |||||||||||
Proceeds from Collection of Notes Receivable | $ 4,900,000 | $ 4,900,000 | |||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 7,119,857 | ||||||||||||
GB Sciences Louisiana, LLC [Member] | |||||||||||||
Deconsolidation, Gain (Loss), Amount | 4,393,242 | ||||||||||||
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC [Member] | |||||||||||||
Proceeds from Divestiture of Businesses | 8,000,000 | ||||||||||||
Earnout Payments | $ 8,000,000 | ||||||||||||
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness | $ 5,224,423 | ||||||||||||
Repayments of Related Party Debt | $ 151,923 | 151,923 | |||||||||||
Debt Instrument, Decrease, Forgiveness | $ 172,500 | 172,500 | |||||||||||
Proceeds from Collection of Notes Receivable | $ 4,150,000 | $ 550,000 | $ 550,000 | 4,900,000 | |||||||||
Note Receivable Satisfied | 8,000,000 | ||||||||||||
Annual Research Contribution Commitment to LSU Assumed by Counter Party | 250,000 | ||||||||||||
Notes Receivable, Net, Scheduled Payments | $ 500,000 | $ 750,000 | |||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,350,000 | ||||||||||||
Notes Receivable, Not Yet Collectible | $ 4,350,000 | $ 4,350,000 | |||||||||||
Notes Receivable, Due Date Extended | $ 4,350,000 | ||||||||||||
Notes Receivable, Amount for Which Proof of Funds is Required | 4,350,000 | ||||||||||||
Notes Receivable, Escrow Deposit Required of Other Party | 250,000 | ||||||||||||
Notes Receivable, Escrow Payment Received | $ 250,000 | ||||||||||||
Notes Receivable, Escrow Payment Not Yet Received | 250,000 | ||||||||||||
Notes Receivable, Retained Amount Not Offset Against Full Balance | $ 50,000 | ||||||||||||
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member] | |||||||||||||
Sale of Stock, Percentage of Ownership | 50.01% |
Note 13 - Sale of 50% Members_4
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Note Receivable (Details) - USD ($) | Mar. 31, 2021 | Nov. 15, 2019 |
Total proceeds | $ 8,000,000 | |
Discount on note receivable | (1,389,408) | |
Wellcana Note [Member] | ||
June 1, 2020 | 500,000 | |
September 1, 2020 | 750,000 | |
December 1, 2020 | 1,000,000 | |
March 1, 2020 | 1,250,000 | |
June 1, 2021 | 1,500,000 | |
September 1, 2021 | 1,500,000 | |
December 1, 2021 | 1,500,000 | |
Discount on note receivable | $ (1,389,408) | |
Net present value | $ 6,610,592 | $ 6,610,592 |
Note 13 - Sale of 50% Members_5
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Deconsolidation (Details) - USD ($) | Nov. 15, 2019 | Mar. 31, 2021 | Mar. 31, 2020 |
Gain on deconsolidation | $ 4,393,242 | $ 4,393,242 | |
GB Sciences Louisiana, LLC [Member] | |||
Present value of promissory note | 6,610,592 | ||
Carrying amount of non-controlling interest | 8,707,651 | ||
Total | 15,318,243 | ||
Carrying amount of assets | 14,715,798 | ||
Carrying amount of liabilities | (3,790,797) | ||
Net assets deconsolidated | $ 10,925,001 |
Note 13 - Sale of 50% Members_6
Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Loss on Modification of Notes Receivable (Details) - USD ($) | Dec. 16, 2020 | Oct. 15, 2020 | Mar. 31, 2021 | Mar. 31, 2020 |
Loss on modification of note receivable | $ (1,895,434) | |||
Wellcana Note [Member] | ||||
Total cash payments to be made by October 15, 2020 | $ 4,900,000 | $ 4,900,000 | ||
Liabilities to be forgiven upon receipt of October 15, 2020 payment | 324,423 | |||
Total receivable (as modified) | $ 5,224,423 | |||
Carrying value of note receivable as of March 31, 2020 | 6,969,720 | |||
Accrued interest as of March 31, 2020 | 150,137 | |||
Total amount receivable (prior to modification) | $ 7,119,857 |
Note 14 - Sale of 100% Member_2
Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries (Details Textual) | Dec. 29, 2020USD ($) | Mar. 24, 2020USD ($) | Nov. 27, 2019USD ($) | Nov. 15, 2019USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2021USD ($) | Jul. 24, 2020USD ($) | Oct. 23, 2017 |
Proceeds from Lines of Credit, Total | $ 375,000 | |||||||||
Gain (Loss) on Amendment to Line of Credit | (650,000) | |||||||||
Proceeds from Sale and Collection of Notes Receivable, Total | 5,051,923 | |||||||||
The July 24 Note [Member] | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 1,025,000 | |||||||||
Gain (Loss) on Amendment to Line of Credit | (650,000) | |||||||||
Teco [Member] | ||||||||||
Management Fees Accrued | $ 850,000 | 850,000 | $ 850,000 | |||||||
Proceeds from Sale and Collection of Notes Receivable, Total | $ 4,000,000 | |||||||||
Notes Receivable Term (Year) | 3 years | |||||||||
Teco [Member] | ||||||||||
Sale of Stock, Percentage of Ownership | 100.00% | 100.00% | 100.00% | |||||||
Proceeds from Divestiture of Businesses | $ 4,000,000 | $ 4,000,000 | ||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | $ 4,000,000 | ||||||||
Notes Receivable, Interest Rate | 8.00% | 8.00% | ||||||||
Notes Receivable, Term of Monthly Installments (Month) | 3 years | |||||||||
Teco [Member] | July 24 Note [Member] | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | |||||||||
Increase (Decrease) in Notes Receivable, Current | (975,000) | |||||||||
Note Receivable, Maximum Allowed Prepayments On Note | 325,000 | |||||||||
Teco [Member] | The July 24 Note [Member] | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 1,025,000 | $ 1,025,000 | 1,025,000 | ||||||
Increase (Decrease) in Notes Receivable, Current | 975,000 | |||||||||
Gain (Loss) on Amendment to Line of Credit | $ (650,000) | |||||||||
Line of Credit [Member] | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | |||||||||
Proceeds from Lines of Credit, Total | $ 485,000 | |||||||||
Teco Note [Member] | Line of Credit [Member] | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | |||||||||
The July 24 Note [Member] | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||
The July 24 Note [Member] | Teco [Member] | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | |||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | |||||||||
The July 24 Note [Member] | Secured Debt [Member] | AJE Management, LLC [Member] | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||
Proceeds from Lines of Credit, Total | $ 375,000 | |||||||||
July 24 Note [Member] | Teco [Member] | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | |||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | |||||||||
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | ||||||||
Teco [Member] | ||||||||||
Sale of Stock, Percentage of Ownership | 75.00% | |||||||||
Sale of Stock, Consideration Received on Transaction | $ 3,000,000 | |||||||||
Sale of Stock, Additional Earn-out Payments | $ 3,000,000 | |||||||||
GB Sciences Nopah, LLC [Member] | ||||||||||
Sale of Stock, Percentage of Ownership | 100.00% | |||||||||
Sale of Stock, Consideration Received on Transaction | $ 300,000 | |||||||||
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | ||||||||||
Sale of Stock, Consideration to Be Received By Means of Debt Reduction | $ 300,000 |
Note 15 - Concentrations (Detai
Note 15 - Concentrations (Details Textual) | 12 Months Ended | |
Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | |
Cash, Uninsured Amount | $ 513,901 | |
Revenues, Total | ||
NEVADA | ||
Revenues, Total | 3,120,620 | |
LOUISIANA | ||
Revenues, Total | $ 569,077 | |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||
Number of Customers | 3 | 2 |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member] | ||
Concentration Risk, Percentage | 18.40% | 26.00% |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member] | ||
Concentration Risk, Percentage | 16.70% | 13.00% |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Three [Member] | ||
Concentration Risk, Percentage | 13.30% | |
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | NEVADA | ||
Concentration Risk, Percentage | 85.00% | |
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | LOUISIANA | ||
Concentration Risk, Percentage | 15.00% |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) - USD ($) | Jun. 14, 2021 | May 11, 2021 | Mar. 24, 2020 | Nov. 15, 2019 | Mar. 31, 2021 | Mar. 31, 2020 |
Class of Warrant or Right, Exercised During Period (in shares) | 35,798,809 | 17,563,000 | ||||
Proceeds from Warrant Exercises | $ 1,075,396 | $ 1,274,790 | ||||
Subsequent Event [Member] | ||||||
Class of Warrant or Right, Exercised During Period (in shares) | 1,672,000 | |||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.03 | |||||
Proceeds from Warrant Exercises | $ 50,160 | |||||
Teco [Member] | ||||||
Proceeds from Divestiture of Businesses | $ 4,000,000 | $ 4,000,000 | ||||
Teco [Member] | Subsequent Event [Member] | ||||||
Proceeds from Divestiture of Businesses | $ 200,000 |